In this installment of the “How I treat ...” series in Blood, the authors outline their clinical algorithm to treat adult patients with relapsed Philadelphia chromosome negative acute lymphoblastic lymphoma (ALL). They note that “allogeneic HCT in second remission is the only curative approach and is the goal when feasible.” The authors note that although there is no standard chemotherapy regimen for relapsed ALL, there are approved agents available, including blinatumomab, nelarabine, and liposomal vincristine. They also discuss the use of monoclonal and cellular investigational therapies and recommend exploration through clinical trials in appropriate patients.
Choose a Topic
- All Topics
- Patient Eligibility
- AML
- Unrelated Donor HCT
- Post-Transplant
- CIBMTR Publications
- GVHD
- ALL
- Lymphomas and CLL
- Preparative Regimens
- Pediatric HCT
- Older Patient HCT
- MDS
- Non-Malignant Disorders
- BMT CTN Publications
- Cord Blood
- Multiple Myeloma
- Sickle Cell Disease
- HLA Matching
- ASH 2015
- ASH 2017
- ASH 2016
- ASH 2020
- CML
- ASH 2018
- Neuroblastoma
Review: Treatment Options for Adults with Relapsed or Refractory Ph- ALL
Jun 2015